ProCE Banner Activity

Call To Action: Integrating New Treatment Options for Urothelial Cancer Into Clinical Practice

Clinical Thought
How are you incorporating new treatment options into your clinical practice for patients with urothelial cancer?

Released: September 15, 2020

Expiration: September 14, 2021

Share

Faculty

Elizabeth Plimack

Elizabeth Plimack, MD, MS

Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Astellas Seattle Genetics

Janssen administered by Scientific Affairs

Faculty Disclosure

Primary Author

Elizabeth Plimack, MD, MS

Assistant Professor
Associate Member
Medical Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Elizabeth R. Plimack, MD, MS has disclosed that she has received funds for research support from Astellas, Bristol-Myers Squibb, Genentech, and Merck, and consulting fees from AstraZeneca, Bristol-Myers Squibb, Flatiron, Genentech, Janssen, Merck, Pfizer, and Seattle Genetics.